Who We Are
SiSaf is a commercial stage biopharmaceutical company headquartered in Guilford, UK with a subsidiary in the USA.
SiSaf is the first company to develop a proprietary Bio-Courier® technology that leverages the unique properties of silicon to overcome the limitations of current drug technologies. This is a powerful platform for developing gene therapy and pharmaceutical products that are optimized to achieve their full therapeutic potential.
We believe Bio-Courier technology will become the pre-eminent non-viral vector for nucleic acid delivery.
The SiSaf Advantage
Portfolio of Gene Therapy and New Therapeutic Entities development candidates create multiple blockbuster product opportunities.
1st to market silicon-based Bio-Courier® technology overcome the limitations of current drug technologies.
Expert team with track record of advancement. State-of-the-art: R&D, Manufacturing and Bio-analytics enables rapid development.
Validated through data, multiple innovation grants, industry leading partners and sought out by clinical leaders.
Hybrid business model of partnered licensing and in-house development to balance revenue generation with ground-breaking R&D.
